Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series
Authors' conclusion
In this series of patients with RAVFs, we did not observe any new fractures and the BMD remained stable after 24 months of RT.
Study context
- Population
- Women with rebound-associated vertebral fractures (RAVFs) after denosumab discontinuation who received 24 months of retreatmentall female
- Participants
- 7 women
- Exposure
- Retreatment with Dmab vs TPT vs zoledronate (Zol) after rebound-associated vertebral fractures
- Dmabn = 3
- TPTn = 3
- Zoln = 1
- Outcome
- Densitometric (bone mineral density (BMD) at lumbar spine (LS), femoral neck (FN), total hip (TH)) and biochemical changes with osteoactive treatment; occurrence of new vertebral and non-vertebral fractures
- Follow-up
- 24 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Mean BMD change
LS
FN
TH
Observational data: associations, not effects.
Further findings
New fractures · 24 months
- No patient suffered new fractures
Original publication
Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series. Osteoporos Int. Published 13 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →